Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $85.08 Average PT from Brokerages

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have been given a consensus rating of “Moderate Buy” by the thirteen research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $85.08.

A number of research analysts have recently issued reports on the stock. The Goldman Sachs Group boosted their price target on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. TD Cowen boosted their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a report on Monday, October 21st. Canaccord Genuity Group reiterated a “buy” rating and set a $111.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, July 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, October 22nd. Finally, Barclays decreased their target price on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a research note on Monday, August 5th.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total value of $1,003,400.00. Following the completion of the sale, the chief executive officer now owns 2,243,985 shares of the company’s stock, valued at approximately $112,580,727.45. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total value of $1,003,400.00. Following the sale, the chief executive officer now owns 2,243,985 shares in the company, valued at $112,580,727.45. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Howard Horn sold 7,465 shares of the firm’s stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares in the company, valued at approximately $4,869,800.76. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,556 shares of company stock valued at $2,519,367 over the last ninety days. 5.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several institutional investors have recently bought and sold shares of the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Ultragenyx Pharmaceutical by 513.8% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 507,095 shares of the biopharmaceutical company’s stock worth $23,677,000 after acquiring an additional 424,476 shares during the last quarter. Clearbridge Investments LLC grew its position in Ultragenyx Pharmaceutical by 0.7% in the 1st quarter. Clearbridge Investments LLC now owns 2,400,854 shares of the biopharmaceutical company’s stock worth $112,096,000 after purchasing an additional 17,362 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Ultragenyx Pharmaceutical by 3.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,568,873 shares of the biopharmaceutical company’s stock valued at $166,632,000 after buying an additional 120,175 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Ultragenyx Pharmaceutical in the 1st quarter valued at about $1,074,000. Finally, Vanguard Group Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 8,700,007 shares of the biopharmaceutical company’s stock worth $406,203,000 after buying an additional 26,575 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE opened at $50.99 on Friday. The stock’s 50-day moving average price is $55.81 and its two-hundred day moving average price is $47.85. Ultragenyx Pharmaceutical has a 12 month low of $34.06 and a 12 month high of $60.37. The company has a market capitalization of $4.70 billion, a PE ratio of -6.98 and a beta of 0.57.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.52) EPS for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.12. The company had revenue of $147.03 million for the quarter, compared to analyst estimates of $123.20 million. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The firm’s quarterly revenue was up 35.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.25) earnings per share. Equities research analysts predict that Ultragenyx Pharmaceutical will post -6.29 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.